Skip Navigation
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Internet Explorer is no longer a supported browser.

This website may not display properly with Internet Explorer. For the best experience, please use a more recent browser such as the latest versions of Google Chrome, Microsoft Edge, and/or Mozilla Firefox. Thank you.

Your Environment. Your Health.

Progress Reports: University of Pennsylvania: Biomarkers of Asbestos Exposure

Superfund Research Program

Biomarkers of Asbestos Exposure

Project Leader: Ian A. Blair
Co-Investigator: Anil Vachani
Grant Number: P42ES023720
Funding Period: 2014-2020
View this project in the NIH Research Portfolio Online Reporting Tools (RePORT)

Learn More About the Grantee

Visit the grantee's eNewsletter page Visit the grantee's Twitter page Visit the grantee's Facebook page

Progress Reports

Year:   2018  2017  2016  2015  2014 

Exposure biomarkers can be used to assess the amount of a chemical that is present within the body. However, asbestos is not present in readily accessible biological fluids; it is inhaled and trapped in lung tissue for long periods of time and so reproducible analytical techniques are critical to ensuring proper validation. Once fully validated and characterized, biomarkers can serve a critical role in detecting levels of exposure, allowing gene-environment interactions to be assessed. The high mobility group box 1 (HMGB1) and its acetylated proteoforms are reported to be a promising biomarker for malignant mesothelioma and asbestos exposure. To overcome the numerous problems with immunoassay-based methodology, the Biomarkers of Asbestos Exposure Project, conducted by Ian A. Blair, Ph.D., Anil Vachani, Ph.D., and their researchers have developed a specific and sensitive assay based on stable isotope dilution and immunopurification to quantify HMGB1 in plasma and serum. The method employed two-dimensional (2D)-nano-ultra high-performance liquid chromatography-parallel reaction monitoring/high resolution mass spectrometry (Weng L, Guo L, Vachani A, Mesaros C, Blair IA. Anal. Chem., 2018). Using this assay, plasma HMGB1 levels were much lower than serum levels, which conclusively demonstrated that HMGB1 was secreted when blood is allowed to clot. Moreover, no endogenous acetylation was detected on HMGB1 in healthy control serum. This exciting new method will evaluate HMGB1 and fibuin-3 proteoforms as biomarkers of asbestos exposure and asbestos-related diseases under the auspices of the Remediation of Asbestos Particles Project in the renewal application.

to Top